Comparative Pharmacology
Head-to-head clinical analysis: SERZONE versus ZYBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERZONE versus ZYBAN.
SERZONE vs ZYBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Serzone (nefazodone) is a serotonin antagonist and reuptake inhibitor (SARI). It blocks postsynaptic 5-HT2 receptors and inhibits serotonin and norepinephrine reuptake, leading to increased serotonergic and noradrenergic neurotransmission.
Bupropion is a selective dopamine and norepinephrine reuptake inhibitor with weak inhibition of serotonin reuptake. Its mechanism in smoking cessation and depression is not fully understood.
Initial 100 mg orally twice daily; titrate to 200-300 mg twice daily. Maximum 600 mg/day.
150 mg orally once daily for 3 days, then increase to 150 mg twice daily for a total treatment duration of 7-12 weeks.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours for nefazodone; steady-state achieved in 3-5 days.
The terminal elimination half-life of bupropion is approximately 21 hours (range 18-24 h), while its active metabolites have longer half-lives: hydroxybupropion ~20 h, threohydrobupropion ~37 h, erythrohydrobupropion ~33 h. Steady state is achieved within 8 days.
Primarily hepatic metabolism; <1% excreted unchanged renally; metabolites excreted in urine (approximately 85%) and feces (approximately 15%).
Renal excretion accounts for approximately 87% of an oral dose, with 42% as unchanged bupropion and its active metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion). Fecal excretion is minimal at <10%.
Category C
Category C
Antidepressant
Antidepressant, Smoking Cessation Aid